Patents by Inventor Laurent Ducry
Laurent Ducry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11833222Abstract: Antibodies having modified constant regions so as to permit conjugation of the antibody to a payload such as a therapeutic agent are described. Preferred antibodies include a mutation at light chain position 180 (positional numbering), most preferably the mutation is to a residue selected from C, K, Q, or a non-natural amino acid. Additional mutations may also be combined with a mutation at position 180; including one or more of light chain (LC) S208, LC S171, LC S182, LC A184, LC V191, LC S202, LC S203, LC T206, heavy chain (HC) S160, HC T190, HC S443, HC S447, HC S139, HC S168, HC V170, HC V176, HC T200, HC S445 according to a positional numbering convention.Type: GrantFiled: September 14, 2020Date of Patent: December 5, 2023Assignee: LONZA LTDInventors: Ramon Gomez De La Cuesta, Jesús Zurdo, Lars Arne Andreas Arnell, Laurent Ducry, Laurence Bonnafoux
-
Publication number: 20210100914Abstract: Antibodies having modified constant regions so as to permit conjugation of the antibody to a payload such as a therapeutic agent are described. Preferred antibodies include a mutation at light chain position 180 (positional numbering), most preferably the mutation is to a residue selected from C, K, Q, or a non-natural amino acid. Additional mutations may also be combined with a mutation at position 180; including one or more of light chain (LC) S208, LC S171, LC S182, LC A184, LC V191, LC S202, LC S203, LC T206, heavy chain (HC) S160, HC T190, HC S443, HC S447, HC S139, HC S168, HC V170, HC V176, HC T200, HC S445 according to a positional numbering convention.Type: ApplicationFiled: September 14, 2020Publication date: April 8, 2021Inventors: Ramon GOMEZ DE LA CUESTA, Jesús ZURDO, Lars Arne Andreas ARNELL, Laurent DUCRY, Laurence BONNAFOUX
-
Patent number: 10953106Abstract: Antibodies having modified constant regions so as to permit conjugation of the antibody to a payload such as a therapeutic agent are described. Preferred antibodies include a mutation at light chain position 180 (positional numbering), most preferably the mutation is to a residue selected from C, K, Q, or a non-natural amino acid. Additional mutations may also be combined with a mutation at position 180; including one or more of light chain (LC) S208, LC S171, LC S182, LC A184, LC V191, LC S202, LC S203, LC T206, heavy chain (HC) S160, HC T190, HC S443, HC S447, HC S139, HC S168, HC V170, HC V176, HC T200, HC S445 according to a positional numbering convention.Type: GrantFiled: February 15, 2016Date of Patent: March 23, 2021Assignee: LONZA LTDInventors: Ramon Gomez De La Cuesta, Jesús Zurdo, Lars Arne Andreas Arnell, Laurent Ducry, Laurence Bonnafoux
-
Patent number: 10294270Abstract: The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; further to a process for the preparation of said protein-drug-conjugates via various intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug conjugates.Type: GrantFiled: February 23, 2012Date of Patent: May 21, 2019Assignees: LONZA LTD, Lonza Guangzhou Nansha Ltd.Inventors: Laurent Ducry, Bernhard Stump, Heilam Wong, Jin She, Gayle Allway
-
Patent number: 10214560Abstract: The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; further to a process for the preparation of said protein-drug-conjugates via various intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug conjugates.Type: GrantFiled: March 23, 2018Date of Patent: February 26, 2019Assignees: LONZA LTD, Lonza Guangzhou Nansha Ltd.Inventors: Laurent Ducry, Bernhard Stump, Heilam Wong, Jin She, Gayle Allway
-
Publication number: 20190026422Abstract: Broadly speaking, the present invention provides a computer-implemented design method and a system to filter a large selection of mutated antibody sequences, identify those mutated antibody sequences which have particular desired properties, such that the identified sequences can be conjugated to a payload and tested in vitro. Thus, the design and system advantageously remove the need for physical testing of the entire initial selection of molecules, which is complex and costly. Only those which match the pre-defined design criteria may be subject to further experimental testing (in vitro testing) to confirm the results of the computer implemented design. Advantageously, by filtering unsafe molecules during the in silico design process, more time can be spent testing drugs which are predicted to be safe for humans.Type: ApplicationFiled: February 15, 2016Publication date: January 24, 2019Inventors: Ramon GOMEZ DE LA CUESTA, Lars Arne Andreas ARNELL, Jesús ZURDO, Laurent DUCRY, Laurence BONNAFOUX
-
Publication number: 20180258136Abstract: The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; further to a process for the preparation of said protein-drug-conjugates via various intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug conjugates.Type: ApplicationFiled: March 23, 2018Publication date: September 13, 2018Inventors: Laurent Ducry, Bernhard Stump, Heilam Wong, Jin She, Gayle Allway
-
Publication number: 20180154017Abstract: Antibodies having modified constant regions so as to permit conjugation of the antibody to a payload such as a therapeutic agent are described. Preferred antibodies include a mutation at light chain position 180 (positional numbering), most preferably the mutation is to a residue selected from C, K, Q, or a non-natural amino acid. Additional mutations may also be combined with a mutation at position 180; including one or more of light chain (LC) S208, LC S171, LC S182, LC A184, LC V191, LC S202, LC S203, LC T206, heavy chain (HC) S160, HC T190, HC S443, HC S447, HC S139, HC S168, HC V170, HC V176, HC T200, HC S445 according to a positional numbering convention.Type: ApplicationFiled: February 15, 2016Publication date: June 7, 2018Inventors: Ramon GOMEZ DE LA CUESTA, Jesús ZURDO, Lars Arne Andreas ARNELL, Laurent DUCRY, Laurence BONNAFOUX
-
Publication number: 20130324706Abstract: The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; further to a process for the preparation of said protein-drug-conjugates via various intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug conjugates.Type: ApplicationFiled: February 23, 2012Publication date: December 5, 2013Inventors: Laurent Ducry, Bernhard Stump, Heilam Wong, Jin She, Gayle Phillips
-
Patent number: 7939698Abstract: The present invention relates to a process for Grignard type reactions comprising mixing at least two fluids in a microreactor having at least two injection points.Type: GrantFiled: July 11, 2007Date of Patent: May 10, 2011Assignee: Lonza AGInventors: Dominique Roberge, Nikolaus Bieler, Laurent Ducry
-
Publication number: 20110009647Abstract: The present invention is directed to a process for the preparation of a diastereomerically pure dibenzoyl-L-tartrate salt of a compound of formula (III) and to products of said process.Type: ApplicationFiled: September 17, 2010Publication date: January 13, 2011Applicant: ASTRAZENECA ABInventors: Rhony Aufdenblatten, Martin Hans Bohlin, Laurent Ducry, Ulrika Lindblad, Mattias Magnusson
-
Publication number: 20100298567Abstract: The invention relates to the nitration of aromatic or heteroaromatic compounds, wherein an activated aromatic or heteroaromatic compound and a nitration agent, optionally in the presence of a solvent, are mixed intensely in a microreactor, and wherein the proportion of the nitration agent to the activated aromatic or heteroaromatic compound, the concentration of nitration agent in the reaction mixture, and the temperature are selected at levels such high that the nitration begins autocatalytically, and wherein the nitration product is obtained after leaving the microreactor and, optionally after an after-reaction time outside the microreactor.Type: ApplicationFiled: January 12, 2006Publication date: November 25, 2010Applicant: LONZA AGInventors: Dominique Roberge, Laurent Ducry
-
Patent number: 7816545Abstract: The present invention is directed to a process for the preparation of a diastereomerically pure dibenzoyl-L-tartrate salt of a compound of formula (III) and to products of said process.Type: GrantFiled: November 14, 2008Date of Patent: October 19, 2010Assignee: AstraZeneca ABInventors: Rhony Aufdenblatten, Martin Hans Bohlin, Laurent Ducry, Ulrika Lindblad, Mattias Magnusson
-
Publication number: 20100174119Abstract: The present invention is related to a method for the production of an aldehyde by reducing an ester of a carboxylic acid with H-DIBAL (diisobutylaluminium hydride).Type: ApplicationFiled: June 30, 2008Publication date: July 8, 2010Inventors: Laurent Ducry, Dominique Roberge, Meinrad Mathier, Michael Gottsponer
-
Publication number: 20090270663Abstract: The present invention relates to a process for Grignard type reactions comprising mixing at least two fluids in a microreactor having at least two injection points.Type: ApplicationFiled: July 11, 2007Publication date: October 29, 2009Applicant: LONZA AGInventors: Dominique Roberge, Nikolaus Bieler, Laurent Ducry
-
Publication number: 20090182157Abstract: The present invention is directed to a process for the preparation of a diastereomerically pure dibenzoyl-L-tartrate salt of a compound of formula (III) and to products of said process.Type: ApplicationFiled: November 14, 2008Publication date: July 16, 2009Inventors: Rhony Aufdenblatten, Martin Hans Bohlin, Laurent Ducry, Ulrika Lindblad, Mattias Magnusson
-
Publication number: 20080119651Abstract: Pyrimidine-5-carboxylates of formula: wherein R is C1-4 alkyl, R1 is C1-4 alkyl, trifluoromethyl, R2 is hydrogen or C1-4 alkyl and X is hydroxy, chlorine or bromine, are prepared from certain 3-oxoalkanoates of formula (II): with urea and orthoesters of formula (III) R2C(OR). The intermediate 2-acyl-3-ureidoacrylate, without being isolated, is reacted to give a 2-hydroxypyrimidine-5-carboxylate[(I), X?OH] or a hydrate thereof, which is optionally converted into the corresponding chloro or bromo compound (I, X?Cl, Br).Type: ApplicationFiled: November 4, 2005Publication date: May 22, 2008Inventors: Laurent Ducry, Bruno Rittiner
-
Publication number: 20060100430Abstract: A process for preparing a 2-alkoxy-6-(trifluoromethyl)pyrimidine-4-ol of the formula I: wherein R is C1-C8 alkyl. First a cyanogen halide, that is, cyanogen chloride ClCN or cyanogen bromide BrCN, is reacted with a C1-C8 alcohol ROH and/or a C1-C8 alcoholate in the presence of a base to give the corresponding symmetric imidocarbonic acid dialkylester of the formula II: In a second step, the imidocarbonic acid diakylester is reacted with trifluoromethyl acetoacetic acid ethyl ester in the presence of ammonia to yield the compound of formula I.Type: ApplicationFiled: February 2, 2004Publication date: May 11, 2006Inventors: Beat Schmidt, Laurent Ducry